| 영문 | adverse effect | 한글 | 역효과, 유해효과 |
|---|---|---|---|
| 설명 | 약물에 의한 치료를 할 때 나타나는 치료목적에 부합되지 않는 불쾌한 작용, 즉 부작용을 역효과로 표현하는 경우가 있다. 세계보건기구(WHO)에서는 역효과란 “예방, 진단, 치료의 목적으로 사람에게 상용량의 약을 사용하였을 때 발현하는 장애로, 의도하지 않은 작용”이라고 정의하고 있다. 약물에 의한 치료를 할 때, 특히 주목하여야 할 일반적인 역효과로서 약물알레르기, 조혈장기 장애, 간-콩팥의 장애, 물질 대사 장애 등이 있다. 이 외에 임산부에게 투여하여 발생한 기형발생, 마약, 각성제, 기타 향정신제에 의한 의존성 형성도 중요하다. |
||
| EPSEM | equal probability of selection method |
|---|---|
| ISIS | image selected in vivo spectroscopy; imaging science and information system; information system-imag... |
| SERS | Stimulus Evaluation/Response Selection [test] |
| ADE | acute disseminated encephalitis; adverse drug event; antibody-dependent enhancement; apparent digest... |
| ADR | activation, depression, repetition [in bone remodeling]; adrenodoxin reductase; Adriamycin; adverse ... |
| MAS | Marker Assisted Selection |
|---|---|
| ADE | Adverse Drug Event |
| ADR | Adverse Drug Reaction |
| AE | Adverse events |
| AE | Adverse effects |
| adverse | Harmful. (18 Nov 1997) |
|---|---|
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| adverse effect | This is an abnormal or harmful effect to an organism caused by exposure to a chemical. It is indicated by some result such as death, a change in food or water consumption, altered body and organ weights, altered enzyme levels, or visible illness. An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the organism, or increases the susceptibility of the organism to other chemical or biological stress. A non-adverse effect will usually be reversed when the organism is no longer being exposed to the chemical. (09 Oct 1997) |
| adverse event | A toxic reaction to a medical therapy. (09 Oct 1997) |
| adverse reaction | Any undesirable or unwanted consequence of a preventive, diagnostic, or therapeutic procedure or regimen. (05 Mar 2000) |
| no-observed-adverse-effect level | The highest dosage administered that does not produce toxic effects. The noael will depend on how closely dosages are spaced (lowest-observed-adverse-effect level and no-observed-effect level) and the number of animals examined. The ultimate objective is usually to determine not the "safe" dosage in laboratory animals but the "safe" dosage for humans. Therefore, the extrapolation most often required of toxicologists is from high-dosage studies in laboratory animals to low doses in humans. (casarett and doull's toxicology: the basic science of poisons, 4th ed) (12 Dec 1998) |
| event, adverse | In pharmacology, an adverse event is any unexpected or dangerous reaction to a drug. (12 Dec 1998) |
| artificial selection | <genetics> The selective breeding by humans towards a desired trait in a plant, animal, or other organism which is of value (usually economic) to the humans. The process operates on the same principles as natural selection. (09 Oct 1997) |
| balancing selection | <genetics> A process of natural selection where heterozygous individuals are more adaptive, and thus selected for more often, than either of the two types of homozygous individuals. (09 Oct 1997) |
| blue white colour selection | <molecular biology, procedure> Method for identifying bacterial clones containing plasmids with inserts. Many modern vectors have their polycloning site within a part of the LacZ gene encoding _ galactosidase, which provides _ complementation in an appropriate mutant E. Coli strain. This means that a re ligated (empty) vector will produce blue colonies when grown on plates containing IPTG and X gal, but colonies with a substantial insert in their plasmid's polycloning site are unable to produce functional _ galactosidase and so produce white colonies. (16 Dec 1997) |
| patient selection | Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols. (12 Dec 1998) |
| medical selection | Preservation, by medical care and treatment, of individuals of pathologic genotypes who would not otherwise reproduce, thus tending to increase the frequency of pathologic genes in the population; conversely, reduction of the frequency of pathologic genes by preventing reproduction of individuals of specified genotype by surgical sterilization or other means. (05 Mar 2000) |
| personnel selection | The process of choosing employees for specific types of employment. The concept includes recruitment. (12 Dec 1998) |
| clonal selection | <cell biology> The process whereby one or more clones, i.e. Cells expressing a particular gene sequence are selected by naturally occurring processes from a mixed population. Generally the clonal selection is for general expansion by mitosis, particularly with reference to B lymphocytes where selection with subsequent expansion of clones occurs as a result of antigenic stimulation only of those lymphocytes bearing the appropriate receptors. (18 Nov 1997) |
| clonal selection theory | A theory which states that each lymphocyte has membrane bound immunoglobulin receptors specific for a particular antigen and once the receptor is engaged, proliferation of the cell occurs such that a clone of antibody producing cells (plasma cell) is produced. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|